CN114601852B - High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract - Google Patents
High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract Download PDFInfo
- Publication number
- CN114601852B CN114601852B CN202011431063.4A CN202011431063A CN114601852B CN 114601852 B CN114601852 B CN 114601852B CN 202011431063 A CN202011431063 A CN 202011431063A CN 114601852 B CN114601852 B CN 114601852B
- Authority
- CN
- China
- Prior art keywords
- extract
- fruiting body
- ganoderma lucidum
- pressure supercritical
- ganoderma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
High-pressure supercritical CO of ganoderma lucidum fruiting body 2 The antitumor drug prepared from the extract is characterized in that the high-pressure supercritical CO of the ganoderma lucidum fruiting body in the drug 2 The total triterpene content of the extract is 0.2-0.3g/g. The antitumor drug is a drug for treating liver cancer. The beneficial effects of the invention are as follows: high-pressure supercritical CO of ganoderma lucidum fruiting body 2 The extract and the preparation thereof are applied to the technical field of preparing antitumor drugs, and provide a new way and means for treating tumors. Through in vitro cytotoxicity activity test and in vivo animal experiments of nude mice, the ganoderma lucidum fruiting body of the invention has high-pressure supercritical CO 2 The extract has obvious inhibition effect on the growth of human liver cancer cells QGY7703 and SK-Hep1 in vitro and has obvious inhibition effect on the growth of human liver cancer cells SK-Hep1 nude mice transplantation tumor. Has important significance for researching the ganoderma lucidum in anti-tumor medicaments.
Description
Technical Field
The invention relates to the technical field of anti-tumor medicines, in particular to an application of a ganoderma lucidum fruiting body high-pressure supercritical extract in preparation of an anti-tumor medicine.
Background
The traditional Chinese medicine Ganoderma is Ganoderma lucidum (of Polyporaceae, ganoderma genus) fungus plant Ganoderma lucidum [Ganoderma lucidum (Leyss.ex Fr.)Karst]Or purple glossy ganoderma [Ganoderma japonicum (Fr.) Lloyd]Is a dried fruit body. Warm nature and sweet taste, has the effects of tonifying middle-jiao and Qi, nourishing and strengthening body resistance, and is clinically used for treating or assisting in treating tumors. Triterpenes and polysaccharides have been considered as the main components of ganoderma lucidum anti-tumor agents to date. The method for extracting triterpene from fruiting body of Ganoderma is ethanol reflux extraction method, but the extraction time is long, and triterpene is also producedAnd (5) organic solvent residues. In contrast, supercritical CO 2 The fluid extraction has the obvious advantages of short extraction time, low extraction temperature, no solvent residue and the like. Hua Zhenggen et al, "high pressure supercritical CO 2 Research on extracting triterpene and sterol components of ganoderma lucidum, namely '5 th period of 2018 of Chinese edible fungi', adopts high-pressure supercritical CO without entrainer 2 Extracting Ganoderma triterpene and sterol by extraction technique, and compared with conventional ethanol reflux extraction method, high pressure supercritical CO is adopted 2 The extraction method improves the triterpene content of Ganoderma by 46.7%. High pressure supercritical CO 2 The extraction method provides a new technology for extracting the triterpene components of the ganoderma lucidum. But high pressure supercritical CO related to fruiting bodies of Ganoderma lucidum 2 The extract has less application research, and high pressure supercritical CO of fruiting body of Ganoderma lucidum is not found 2 The extract is applied to anti-tumor report.
Disclosure of Invention
The invention aims to provide a ganoderma lucidum fruiting body high-pressure supercritical CO 2 The anti-tumor medicine prepared from the extract provides a new means for treating tumors.
The technical scheme adopted by the invention is as follows: an antitumor drug prepared from Ganoderma fruiting body high pressure supercritical CO2 extract is characterized in that the drug contains Ganoderma fruiting body high pressure supercritical CO 2 The total triterpene content of the extract is 0.2-0.3g/g.
The invention firstly carries out high-pressure supercritical CO on the ganoderma lucidum fruiting body 2 The extract is applied to the technical field of preparing anti-tumor medicaments, and provides a new means for treating tumors. The ganoderma lucidum extract has high effective content and high purity, and fully plays the anti-tumor effect of ganoderma lucidum.
The antitumor drug is a drug for treating liver cancer. The liver cancer is the most sensitive to the invention, the liver is the detoxification organ of human body, the deposited toxin is the most, the invention with high effective content and purity of the ganoderma fully plays the detoxification efficacy of the ganoderma, and is not interfered by other medicinal components.
High-pressure supercritical CO of ganoderma lucidum fruiting body 2 The extraction method of the extract comprises the following steps: loading Ganoderma fruiting body fine powder into supercritical CO 2 Extraction pressure of extraction kettle of extraction device is greater than35 Extracting at 40-50 deg.C under MPa for 4 hr for CO 2 The flow is 12L/h, and the extract is collected from the separation kettle.
The extract also comprises a high-pressure supercritical extract preparation of ganoderma lucidum fruiting body.
The Ganoderma lucidum high-pressure supercritical extract preparation is prepared by adding pharmaceutically acceptable adjuvants into Ganoderma lucidum high-pressure supercritical extract, and making into oral preparation.
The oral preparation is tablet, capsule, pill, granule, suspension, dripping pill, drop or oral liquid.
The beneficial effects of the invention are as follows: high-pressure supercritical CO of ganoderma lucidum fruiting body 2 The extract and the preparation thereof are applied to the technical field of preparing antitumor drugs, and provide a new way and means for treating tumors. Through in vitro cytotoxicity activity test and in vivo animal experiments of nude mice, the ganoderma lucidum fruiting body of the invention has high-pressure supercritical CO 2 The extract has obvious inhibition effect on the growth of human liver cancer cells QGY7703 and SK-Hep1 in vitro and has obvious inhibition effect on the growth of human liver cancer cells SK-Hep1 nude mice transplantation tumor. Has important significance for researching the ganoderma lucidum in anti-tumor medicaments.
Drawings
FIG. 1 Ganoderma lucidum fruiting body high pressure supercritical CO 2 Quantitative response curve of extract G85 action for 72h on QGY7703 and SK-Hep1 cell growth
FIG. 2 shows high-pressure supercritical CO of Ganoderma lucidum fruiting body 2 The extract G85 has an inhibition effect on the growth of human liver cancer SK-Hep1 nude mice transplanted tumor, wherein the A graph is the influence of G85 on the volume of transplanted tumor, the B graph is the influence of G85 on the weight of mice, the C graph is the influence of G85 on the weight of mice transplanted tumor at the end of the experiment, and the D graph is the inhibition rate of G85 on the growth of human liver cancer SK-Hep1 nude mice transplanted tumor.
Detailed Description
The invention is described in detail below by way of the following description of embodiments of the invention, but not by way of limitation.
High-pressure supercritical CO utilizing ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract and Ganoderma fruiting body high pressure supercriticalCO 2 The extraction method of the extract comprises the following steps: loading Ganoderma fruiting body fine powder into supercritical CO 2 Extracting kettle of extracting device, extracting pressure higher than 35 MPa, extracting temperature 40-50deg.C, extracting time 4h, CO 2 The flow is 12L/h, and the extract is collected from the separation kettle. The extract also comprises a high-pressure supercritical extract preparation of ganoderma lucidum fruiting body. The Ganoderma lucidum high-pressure supercritical extract preparation is prepared by adding pharmaceutically acceptable adjuvants into Ganoderma lucidum high-pressure supercritical extract, and making into oral preparation.
The total triterpene content of the high-pressure supercritical CO2 extract of Ganoderma fruiting body in the medicine is 0.2-0.3g/g. Can be used as medicine for treating liver cancer. The oral preparation is tablet, capsule, pill, granule, suspension, dripping pill, drop or oral liquid.
Example 1
The extraction method of the high-pressure supercritical CO2 extract of the ganoderma lucidum fruiting body comprises the following steps:
loading 1kg of Ganoderma fruiting body fine powder into extraction kettle of supercritical CO2 extraction device, extracting at 40deg.C under 36MPa for 4 hr at CO2 flow rate of 12L/h, collecting extract from the separation kettle, and vacuum drying at 65deg.C (designated as G36).
Example 2
High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Extraction of the extract:
loading 1kg of Ganoderma fruiting body fine powder into supercritical CO 2 Extracting kettle of extracting device with extracting pressure of 85 MPa, extracting temperature 50deg.C, extracting time of 4 hr, CO 2 The flow rate is 12L/h, the extract is collected from the separation kettle and dried in vacuum at 65 ℃ to obtain the product (named G85).
Application examples
Biological experiment and analysis of anticancer action of the high-pressure supercritical CO2 extract of Ganoderma lucidum fruiting body of example 2
1. Materials and methods
Cell lines and reagents human hepatoma cell lines QGY7703 and SK-Hep1. Culturing the cells in RPMI 1640 culture solution containing 10% calf serum, and placing at 37deg.C and 5% saturated humidity CO 2 CulturingCulturing in a box.
QGY7703 and SK-Hep1 cells in logarithmic growth phase for inhibition of cell proliferation in vitro were used in 1X 10 5 Inoculating initial concentration of/ml into 96-well culture plate, 180 μl each, adding high-pressure supercritical CO of Ganoderma fruiting body of different concentrations into experimental group 2 20 μl/well of extract was added to a cell control group containing an equivalent concentration of DMSO in serum-free medium, and a blank group containing 180 μl of RPMI 1640 and 20 μl of drug-free solvent was added, with 3 wells per group. After 72h cell incubation, 5 mg/ml MTT 20 μl/well was added, incubated at 37℃for 4h and centrifuged (2000 rpm,10 min), the supernatant carefully aspirated, 150 μl/well DMSO was added and mixed well, the OD of each well was measured at 570 nm wavelength for each group, and the inhibition of cell growth was calculated as = (1-drug treated well mean OD/cell control well mean OD) ×100%. And drawing a dose-response curve by taking the drug concentration as a horizontal axis and the cell growth inhibition rate as a vertical axis. Calculation of drug concentration at 50% inhibition of cell growth by Logit method, IC 50 Values, experiments were repeated 3 times and averaged.
In vivo anti-tumor experiments with nude mice transplanted tumors BALB/C mice (6-8 weeks old; 20.0.+ -. 2.0 g) were obtained from Shanghai Laike laboratory animals Co., ltd (Shanghai, china). Mice were randomly divided into 4 groups: negative control group, positive control group (cyclophosphamide injection per abdominal cavity: 30.0mg/kg every 2 days), ganoderma fruiting body high pressure supercritical CO 2 Extract treatment group (75 mg/kg or 300mg/kg of stomach per day). Each group of mice was injected 20mm at the armpit of the right forearm 3 SK-Hep1 solid tumor. When the tumor grows to 100mm 3 At this time, the mice were continuously dosed for 43 days and their body weights were continuously measured. Tumor volumes were measured every 3 days. At the end of the experiment, tumors were excised and weighed.
Results of
High-pressure supercritical CO of ganoderma lucidum fruiting body with in-vitro anti-tumor fine action 2 The extract (G85) has remarkable inhibition effect on QGY7703 and SK-Hep1 cell proliferation. Medicine acts on QGY7703 cell 72h IC 50 The value is 75.34+ -0.63 μg/mL; IC acting on SK-Hep1 cells 72h 50 The value was 141.12.+ -. 5.09. Mu.g/mL (FIG. 1). Experimental results show that the compound has anti-tumor activity.
High-pressure supercritical CO of ganoderma lucidum fruiting body with in-vivo dynamic anti-tumor effect 2 Extract (G85) inhibited tumor growth in a dose-dependent manner in SK-Hep1 xenograft tumor model. The tumor inhibition rates for the lavage of nude mice were 28.2% and 55.4% for 75mg/kg and 300mg/kg G85, respectively, compared to the control group (FIG. 2). 75 The weight of animals in the mg/kg and 300mg/kg G85 continuous administration for 43 days was compared with that of the negative control group, and the weight of animals in the cyclophosphamide positive control group was significantly reduced without decreasing. Indicating high-pressure supercritical CO of ganoderma lucidum fruiting body 2 The extract (G85) has no toxicity to animals at antitumor doses.
Claims (4)
1. High-pressure supercritical CO of ganoderma lucidum fruiting body 2 The anti-liver cancer medicine prepared from the extract is characterized in that the high-pressure supercritical CO of the ganoderma lucidum fruiting body in the medicine 2 The total triterpene content of the extract is 0.2-0.3g/g, and the Ganoderma fruiting body has high pressure supercritical CO 2 The extraction method of the extract comprises the following steps: loading Ganoderma fruiting body fine powder into supercritical CO 2 Extracting kettle of extracting device with extracting pressure of 85 MPa, extracting temperature 50deg.C, extracting time of 4 hr, CO 2 Collecting the extract from the separating kettle at flow rate of 12L/h, and vacuum drying at 65deg.C.
2. The high-pressure supercritical CO of Ganoderma fruiting body according to claim 1 2 The anti-liver cancer medicine prepared from the extract is characterized in that the medicine is ganoderma lucidum fruiting body high-pressure supercritical CO 2 The extract can be made into pharmaceutical preparation.
3. The high-pressure supercritical CO of Ganoderma fruiting body of claim 2 2 The anti-liver cancer medicine prepared by the extract is characterized in that the preparation is high-pressure supercritical CO of ganoderma lucidum fruiting body 2 The extract is added with pharmaceutically acceptable auxiliary materials to prepare the oral preparation.
4. A ganoderma lucidum fruiting body high-pressure supercritical CO according to claim 3 2 An anti-liver cancer medicine prepared from the extract is characterized in thatThe oral preparation is tablets, capsules, pills, granules, suspension or drops.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011431063.4A CN114601852B (en) | 2020-12-09 | 2020-12-09 | High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011431063.4A CN114601852B (en) | 2020-12-09 | 2020-12-09 | High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114601852A CN114601852A (en) | 2022-06-10 |
| CN114601852B true CN114601852B (en) | 2023-07-18 |
Family
ID=81856710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011431063.4A Active CN114601852B (en) | 2020-12-09 | 2020-12-09 | High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114601852B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293789B (en) * | 2011-09-06 | 2014-03-12 | 上海市农业科学院 | Method for extracting triterpenoids from ganoderma lucidum sporocarp |
| CN104274498B (en) * | 2014-09-18 | 2018-05-15 | 开平健之源保健食品有限公司 | A kind of high efficiency anti-tumor Ganodenna Lucidum P.E and preparation method thereof |
| CN104435005A (en) * | 2014-12-22 | 2015-03-25 | 芝圣（天津）生物科技有限公司 | Method for refining triterpene compound in antrodia |
-
2020
- 2020-12-09 CN CN202011431063.4A patent/CN114601852B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114601852A (en) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6209579B2 (en) | Pharmaceutical composition that is regarded as a supplementary medicine | |
| CN104644697B (en) | The preparation method and applications of ganoderma lucidum Ultramicro-powder | |
| CN112043715A (en) | Application of ganoderic acid A in preparation of medicine for improving GABAergic neuron system dysfunction | |
| CN106309506B (en) | Probiotics composition with menstruation regulating function and application thereof | |
| CN101940696B (en) | Method for preparing Chinese medicinal compound Zengshengping | |
| CN114601852B (en) | High-pressure supercritical CO of ganoderma lucidum fruiting body 2 Antitumor drug prepared from extract | |
| CN110664883B (en) | A pharmaceutical composition with vital essence generation effect | |
| Liu et al. | Pharmacological and anti-tumor activities of Ganoderma spores processed by top-down approaches | |
| CN1939396A (en) | Suberect spatholobus stem extract with antineoplastic function and its making method | |
| CN112494520B (en) | Application of gecko or extract thereof in preparing anti-depression drug | |
| CN111184758B (en) | Composition containing caulis Mahoniae alcohol extract and cordycepin, preparation and application thereof | |
| CN115300624A (en) | Application of ginsenoside and PD-1 blocker in preparation of head and neck squamous cell carcinoma resisting medicine | |
| CN110141589B (en) | Folium kaempferiae extract and preparation method and application thereof | |
| CN102961443B (en) | Rhizoma menispermi antineoplastic extract, Preparation method and use | |
| CN115671149B (en) | Ganoderma lucidum spore oil and application thereof in preparing medicines for resisting cancer-induced fatigue | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN101336918B (en) | Use of annonaceous acetogenins in preparing medicine for treating lung cancer or breast cancer | |
| CN107927745B (en) | A Chinese medicinal health food composition, and its preparation method and preparation | |
| CN115400176B (en) | Preparation method and application of lychee seed extract | |
| CN104523698B (en) | Application of the hederagenin in preparation anti-endometrial cancer cell HEC-1 tumour medicine | |
| JP2003252780A (en) | Apoptosis inducer | |
| CN109758493B (en) | Application of cardamine hirsute and extract thereof in preparation of drugs for preventing or treating arrhythmia | |
| CN107158205B (en) | A pharmaceutical composition for treating hypertension | |
| CN104906150A (en) | Application of grifola frondosa in preparation of anti-depression products | |
| CN1970034B (en) | Chinese medicine containing gadol and tuckahoe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |